Status: Recruiting
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or CD19 or both sequentially in the treatment of Relapsed/ Refractory Autoimmune Disease such as Sjogren's Syndrome or Systemic Lupus Erythematosus and other Autoimmune Disease.
Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 21-90Biological sex: AllType: InterventionalSponsor: Essen BiotechUpdated: Nov 5, 2024Locations: 1
Eligibility criteria
Expected survival time ≥3 months; [+7]
Malignant tumors other than R/R AID disease in the 5 years prior to screening, e... [+10]